The study team investigated how Mavacamten, a small-molecule inhibitor of beta-cardiac myosin ATPase, affects skeletal muscle myosin isolated from rabbit diaphragm. The diaphragm contains roughly equal proportions of slow, Type I and fast, Type II fibers, and the authors pointed out that beta-MyHC expression is not limited to ventricular myocardium but is also present in slow skeletal fibers. Using an in vitro motility assay, investigators measured the velocity of actin and regulated thin filaments moved by native diaphragm myosin. Data indicated a clear, dose-dependent decrease in filament velocity, and the authors reported an apparent IC50 of 1350 nM. The inhibition reversed upon washout in the assay, which the study team interpreted as a non-permanent modulatory effect rather than irreversible myosin inactivation. The report did not present in vivo dosing regimens, systemic pharmacokinetics, or patient respiratory function measurements; those details were not provided in this preprint.
Short, direct facts matter. The diaphragm relies on both fiber types for sustained ventilation. If a drug reduces myosin-driven shortening velocity in a concentration-dependent manner, then contractile performance could be affected under load. The authors posed this concern explicitly, arguing that the observed in vitro effects warrant clinical respiratory monitoring in patients receiving the drug for cardiomyopathy.
To test fiber-type specificity, the investigators isolated pure slow myosin from M. soleus and pure fast myosin from M. psoas. Both isoforms showed susceptibility to Mavacamten, but slow myosin exhibited nearly 20-fold greater sensitivity than fast myosin according to the authors’ measurements. The study team also compared slow skeletal myosin sensitivity to previously characterized beta-cardiac myosin and reported that slow myosin showed even higher sensitivity than the cardiac isoform. These relative differences in potency emerged from the same in vitro motility platform; the report did not extend these comparisons into intact muscle preparations or whole-animal respiratory function tests. The data therefore speak to isoform-specific biochemical sensitivity rather than direct clinical effect sizes.
The implication is mechanistic and clinical at once. Slow fibers—enriched in beta-MyHC—contribute importantly to tonic, fatigue-resistant contraction in the diaphragm. A preferential reduction of slow-fiber motor activity could shift the balance of diaphragmatic force generation and endurance. Authors noted this risk, recommending that clinicians consider respiratory monitoring when patients are exposed to the drug, but they did not supply clinical monitoring protocols or threshold values in this manuscript.
Further experiments in the report separated two apparent modes of action. First, investigators observed that Mavacamten promotes an OFF state of myosin, which likely diminishes the pool of active motors available to interact with actin filaments. Second, the drug appeared to modulate the actomyosin biochemical cycle itself, altering motor kinetics in ways that reduce net filament sliding velocity. The authors described these as complementary mechanisms that together reduce contractile output in the assay system. They emphasize mechanistic interpretation based on isolated proteins and in vitro filament motility.
Translating these mechanisms to patients requires caution. The study is a preprint and presents biochemical and biophysical data from rabbit muscle preparations; human in vivo effects were not measured in this report. The authors therefore called for respiratory function monitoring in patients receiving Mavacamten, given the diaphragm’s mixed fiber composition and reliance on slow fibers for sustained respiration. They also flagged reversibility in the assay as an important observation: washout restored motility, suggesting that inhibition may be pharmacologically reversible rather than permanently damaging.
Limitations and unanswered questions remain concrete and numerous. The manuscript did not include in vivo respiratory physiology, patient safety data, or dosing information for systemic exposure comparable to the IC50 observed in vitro. The preprint status indicates results have not undergone peer review. Investigators reported biochemical potency and mechanistic readouts only; the magnitude of any clinically relevant respiratory impairment, the exposure thresholds in patients, and suitable monitoring strategies are not documented here. These gaps define the next steps: determine whether therapeutic exposures in patients reach concentrations that inhibit diaphragm myosin, test intact muscle and whole-animal respiratory function, and establish clinical monitoring parameters if risk is confirmed.